Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC) Meeting Abstract
| Authors: | Olivera, M.; Jhaveri, K.; Juric, D.; Bedard, P. L.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; Schmid, P.; Turner, N.; Varga, A.; Lei, G.; Royer-Joo, S.; Thomas, P.; Schutzman, J. L.; Saura, C. |
| Abstract Title: | Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC) |
| Meeting Title: | 43rd Annual San Antonio Breast Cancer Symposium (2020 SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 81 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2020 Dec 8-11 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2021-02-01 |
| Language: | English |
| ACCESSION: | WOS:000618737700337 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.SABCS20-PS11-11 |
| Notes: | Meeting Abstract: PS11-11 -- This symposium was held virtually due to COVID-19 -- Source: Wos |
